DILIsym Releases NAFLDsym® Version 2A
Summary
Dr. Scott Q Siler, chief scientific officer of DILIsym Services, said: “We are excited about the release of NAFLDsym v2A, as we believe it will assist the pharmaceutical industry by bringing effective medications to non-alcoholic steatohepatitis (NASH) patients in a timely and cost-efficient manner. NAFLDsym and IPFsym are designed for target or compound evaluation of therapeutic efficacy in nonalcoholic fatty liver disease (NAFLD or NASH) and idiopathic pulmonary fibrosis (IPF), respectively. In addition to performing consulting services using the modeling software, the expert scientific team engages clients from initial program design through data input and “results” interpretation. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical, biotechnology, and chemical agents. Our software is licensed and used in the conduct of drug research by major pharmaceutical, biotechnology, chemical, and consumer goods companies and regulatory agencies worldwide.